Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Study to Evaluate the Efficacy and Safety of APX001 in Non Neutropenic Patients With Candidemia, With or Without Invasive Candidiasis, Inclusive of Patients With Suspected Resistance to Standard of Care Antifungal Treatment

Next Previous
X
Search
Trial Profile

An Open-Label Study to Evaluate the Efficacy and Safety of APX001 in Non Neutropenic Patients With Candidemia, With or Without Invasive Candidiasis, Inclusive of Patients With Suspected Resistance to Standard of Care Antifungal Treatment

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fosmanogepix (Primary) ; Fosmanogepix (Primary)
  • Indications Candidaemia
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Basilea Pharmaceutica; Pfizer

    • Most Recent Events

    • 19 Aug 2023 Results published in the Journal of Antimicrobial Chemotherapy.
    • 25 Oct 2020 Results presented at the IDWeek 2020
    • 25 Oct 2020 Results of a subset analysis assessing outcomes in patients with varying degrees of renal insufficiency presented at the IDWeek 2020

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top